CONSTILAC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Constilac, and what generic alternatives are available?
Constilac is a drug marketed by Alra and is included in one NDA.
The generic ingredient in CONSTILAC is lactulose. There are twenty drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the lactulose profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Constilac
A generic version of CONSTILAC was approved as lactulose by HIKMA on July 3rd, 1995.
Summary for CONSTILAC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 28 |
Clinical Trials: | 1 |
Patent Applications: | 3,594 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CONSTILAC at DailyMed |
Recent Clinical Trials for CONSTILAC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tampa General Hospital | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for CONSTILAC
US Patents and Regulatory Information for CONSTILAC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alra | CONSTILAC | lactulose | SOLUTION;ORAL | 071054-001 | Jul 26, 1988 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |